Epigenomics

Epigenomics is a molecular diagnostics company focused on the development of blood-based DNA methylation tests for the early the detection of cancer. The Epi proColon test has recently become the first and only FDA approved blood test for colorectal cancer screening. Epi proColon, HCCBloodTest, and the Epi proLung tests are available in Europe as CE-marked IVDs. Industry partners, as well as the medical and life science communities, can access our expansive intellectual property portfolio. Epigenomics has been granted over 60 patents, in addition to many others that have been filed. These patents cover DNA methylation technologies and biomarkers, as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.